Drug intelligence / Profile preview

AR-C165395XX

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AR-C165395XX is an orally administered small molecule drug developed by AstraZeneca for the treatment of type 2 diabetes mellitus. It was investigated in a phase I clinical trial to assess its pharmacodynamics after repeated dosing in subjects with type 2 diabetes. The precise mechanism of action remains undefined or unknown, and it is classified as an antihyperglycaemic agent. There are no reported approvals or known adverse events associated with this compound.

Beyond the preview

Go deeper on AR-C165395XX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR-C165395XX.

Explore the full profile